AU2018231842B2 - Topical delivery systems for active compounds - Google Patents

Topical delivery systems for active compounds Download PDF

Info

Publication number
AU2018231842B2
AU2018231842B2 AU2018231842A AU2018231842A AU2018231842B2 AU 2018231842 B2 AU2018231842 B2 AU 2018231842B2 AU 2018231842 A AU2018231842 A AU 2018231842A AU 2018231842 A AU2018231842 A AU 2018231842A AU 2018231842 B2 AU2018231842 B2 AU 2018231842B2
Authority
AU
Australia
Prior art keywords
formulation
oil
ethoxylated
oily
active agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018231842A
Other languages
English (en)
Other versions
AU2018231842A1 (en
Inventor
Sharon GARTI LEVI
Nissim Garti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lyotropic Delivery Systems Ltd
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
Lyotropic Delivery Systems Ltd
Yissum Research Development Co of Hebrew University of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lyotropic Delivery Systems Ltd, Yissum Research Development Co of Hebrew University of Jerusalem filed Critical Lyotropic Delivery Systems Ltd
Publication of AU2018231842A1 publication Critical patent/AU2018231842A1/en
Assigned to YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD, LYOTROPIC DELIVERY SYSTEMS Ltd reassignment YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD Amend patent request/document other than specification (104) Assignors: LYOTROPIC DELIVERY SYSTEMS (LDS), YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD
Application granted granted Critical
Publication of AU2018231842B2 publication Critical patent/AU2018231842B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/723—Xanthans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2018231842A 2017-03-07 2018-03-07 Topical delivery systems for active compounds Active AU2018231842B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762467863P 2017-03-07 2017-03-07
US62/467,863 2017-03-07
PCT/IL2018/050265 WO2018163176A1 (en) 2017-03-07 2018-03-07 Topical delivery systems for active compounds

Publications (2)

Publication Number Publication Date
AU2018231842A1 AU2018231842A1 (en) 2019-09-19
AU2018231842B2 true AU2018231842B2 (en) 2024-03-21

Family

ID=61692208

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018231842A Active AU2018231842B2 (en) 2017-03-07 2018-03-07 Topical delivery systems for active compounds

Country Status (8)

Country Link
US (2) US20210137829A1 (https=)
EP (1) EP3592336A1 (https=)
JP (1) JP7250689B2 (https=)
CN (1) CN110545796A (https=)
AU (1) AU2018231842B2 (https=)
CA (1) CA3055159A1 (https=)
IL (1) IL268773B2 (https=)
WO (1) WO2018163176A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3076555B1 (fr) * 2018-01-11 2020-01-24 Jafer Enterprises R&D Sl Materiau polymerique solide impregne d'une substance organique volatile et d'un ester particulier et ses utilisations
WO2020123306A1 (en) 2018-12-14 2020-06-18 Mary Kay Inc. Cosmetic compositions
EP3986383A4 (en) * 2019-06-20 2023-07-19 Lyotropic Delivery Systems Ltd. POLYMERIC FLEXIBLE FILMS INCLUDING NANODOMAINS AND/OR A BIOACTIVE AGENT AND METHODS FOR PRODUCING THEM
CN114401770A (zh) * 2019-09-29 2022-04-26 莱雅公司 用于护理角蛋白材料的化妆品组合物
CN110960682B (zh) * 2019-12-13 2020-12-25 厦门大学 一种pH调控凝胶高压后融化态时长增强药物负载的方法
US20230113554A1 (en) * 2019-12-16 2023-04-13 Ao Technology Ag Non-stick antibiotic gels
CN111632191B (zh) * 2020-05-11 2021-12-17 西安理工大学 一种释药磷酸钙基骨水泥的制备方法
US12109290B2 (en) 2020-12-29 2024-10-08 Kao Usa Inc. Hair shine compositions
EP4112043A1 (en) * 2021-06-30 2023-01-04 GSK Consumer Healthcare SARL Nano-complex composition comprising diclofenac
CN113786382B (zh) * 2021-11-04 2024-05-28 浙江得恩德制药股份有限公司 一种盐酸特比萘芬凝胶及制备方法
EP4342450A1 (en) * 2022-09-21 2024-03-27 Haleon CH SARL Hydroalcoholic topical diclofenac formulations
EP4342449A1 (en) * 2022-09-21 2024-03-27 Haleon CH SARL Hydroalcoholic single phase gel compositions for topical delivery of diclofenac
WO2025062440A1 (en) * 2023-09-20 2025-03-27 Pulse Pharmaceuticals Pvt. Ltd Topical nano-dispersion compositions and their preparation thereof
US20250099369A1 (en) * 2023-09-27 2025-03-27 Andros Pharmaceuticals Co., Ltd. Topical delivery compositions comprising non-steroidal anti-inflammatory drugs
WO2025153330A1 (en) * 2024-01-15 2025-07-24 JeNaCell GmbH Microemulsion systems for the incorporation of poorly-water soluble compounds into bacterial cellulose
WO2025193822A1 (en) * 2024-03-13 2025-09-18 Menning Mark Michael Aqueous compositions of poorly water-soluble compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010045415A2 (en) * 2008-10-16 2010-04-22 Novartis Ag Topical nsaid compositions having sensate component
US20140045858A1 (en) * 2011-03-28 2014-02-13 Yiming Wang Compound preparation treating alzheimer's disease and preparation method thereof
WO2016038553A1 (en) * 2014-09-10 2016-03-17 Novartis Consumer Health S.A. Topical diclofenac sodium compositions

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2660554B1 (fr) * 1990-04-05 1992-07-03 Oreal Composition cosmetique ou dermo-pharmaceutique aqueuse contenant en suspension des spherouides hydrates d'une substance lipidique hydrophile.
JPH06509099A (ja) 1991-07-03 1994-10-13 サノ・コーポレーシヨン ジクロフエナツクの経皮デリバリーに対する組成物及び方法
AU2953497A (en) 1996-05-13 1997-12-05 Novartis Consumer Health S.A. Topical composition
US7182950B2 (en) 2002-06-12 2007-02-27 Nutralease Ltd. Nano-sized self-assembled liquid dilutable vehicles
EP1598060A1 (en) 2004-05-18 2005-11-23 Nestec S.A. Oil-in-water emulsion for delivery
CN101360481A (zh) 2005-11-22 2009-02-04 雀巢技术公司 水包油乳液及其用于功能性输送的用途
EP1963270B1 (en) 2005-12-09 2009-08-05 Cerecon AG Quaternary 3 -amido, n-methylpyridinium salts as anti -inflammatory agents
WO2008058366A1 (en) 2006-09-28 2008-05-22 Université de Montréal Oil-in-water emulsions, methods of use thereof, methods of preparation thereof and kits thereof
GB0623838D0 (en) 2006-11-29 2007-01-10 Malvern Cosmeceutics Ltd Novel compositions
GB0704846D0 (en) 2007-03-13 2007-04-18 Futura Medical Dev Ltd Topical pharmaceutical formulation
CA2697458C (en) 2007-06-08 2016-02-09 Troikaa Pharmaceuticals Ltd. Non-aqueous topical solution of diclofenac and process for preparing the same
EP2055298A1 (en) 2007-10-30 2009-05-06 Novartis AG Topical composition
SG10201401297QA (en) * 2009-04-08 2014-08-28 Cadila Healthcare Ltd Stable pharmaceutical compositions of diclofenac
CN104428003B (zh) 2012-07-12 2020-03-10 辉凌公司 双氯芬酸制剂
CN103655459A (zh) * 2013-12-19 2014-03-26 中国药科大学 一种多功能微乳凝胶制剂及其制备工艺
CN113788831B (zh) * 2021-10-15 2023-01-17 常州大学 二氢吲嗪并吡咯酮衍生物及类似物及其合成方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010045415A2 (en) * 2008-10-16 2010-04-22 Novartis Ag Topical nsaid compositions having sensate component
US20140045858A1 (en) * 2011-03-28 2014-02-13 Yiming Wang Compound preparation treating alzheimer's disease and preparation method thereof
WO2016038553A1 (en) * 2014-09-10 2016-03-17 Novartis Consumer Health S.A. Topical diclofenac sodium compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SPERNATH ET AL: JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 119, no. 3, 22 May 2007 (2007-05-22), pages 279 - 290, XP022087328, ISSN: 0168-3659, DOI: 10.1016/J.JCONREL.2007.02.014 *

Also Published As

Publication number Publication date
CA3055159A1 (en) 2018-09-13
US20240350401A1 (en) 2024-10-24
JP7250689B2 (ja) 2023-04-03
RU2019129711A3 (https=) 2021-06-17
AU2018231842A1 (en) 2019-09-19
IL268773B1 (en) 2023-01-01
JP2020514342A (ja) 2020-05-21
IL268773B2 (en) 2023-05-01
WO2018163176A1 (en) 2018-09-13
IL268773A (en) 2019-10-31
US20210137829A1 (en) 2021-05-13
RU2019129711A (ru) 2021-04-07
EP3592336A1 (en) 2020-01-15
CN110545796A (zh) 2019-12-06

Similar Documents

Publication Publication Date Title
US20240350401A1 (en) Topical delivery systems for active compounds
Labie et al. Hydrogels for dermal and transdermal drug delivery
Khan et al. Development and in vitro/ex vivo evaluation of lecithin‐based deformable transfersomes and transfersome‐based gels for combined dermal delivery of meloxicam and dexamethasone
Muzaffar et al. Review on microemulsion as futuristic drug delivery
Katiyar et al. Microemulsions: A novel drug carrier system
Pund et al. Transcutaneous delivery of leflunomide nanoemulgel: Mechanistic investigation into physicomechanical characteristics, in vitro anti-psoriatic and anti-melanoma activity
Manconi et al. Penetration enhancer containing vesicles as carriers for dermal delivery of tretinoin
Ki et al. A new injectable liquid crystal system for one month delivery of leuprolide
de Araújo et al. Mucoadhesive in situ gelling liquid crystalline precursor system to improve the vaginal administration of drugs
Singh et al. Microemulsions: current trends in novel drug delivery systems
CN107257680A (zh) 用于眼科药物递送的自乳化药物递送体系(sedds)
US9084818B2 (en) Topical dermal delivery compositions using self assembling nanoparticles with cetylated components
Kushwah et al. Microemulgel: a novel approach for topical drug delivery
Al-Suwayeh et al. Design and dermatokinetic appraisal of lornoxicam-loaded ultrafine self-nanoemulsion hydrogel for the management of inflammation: In vitro and in vivo studies
Kankane et al. Emulgel: A dual release system for hydrophobic drug delivery
Mohamed et al. Tailoring of spanlastics for promoting transdermal delivery of irbesartan: In vitro characterization, ex vivo permeation and in vivo assessment
Azeez et al. Nanoemulgel as a recent drug delivery system
Evelyn et al. Development and evaluation of microemulsion based gel (MBGs) containing econazole nitrate for nail fungal infection
Yasir Siddique et al. Formulation of microemulsion-based gels for enhanced topical administration of nonsteroidal anti-inflammatory drugs
Mehta et al. Microemulsions: A potential novel drug delivery system
Singh et al. Formulation development and characterization of nanoemulsion-based gel for topical application of raloxifene hydrochloride
Kamra et al. Topical liposomal gel: A review
Begur et al. Development and characterization of nanoemulgel based transdermal delivery system for enhancing permeability of tacrolimus
Kumbhar et al. Development and characterization of water-in-oil microemulsion for transdermal delivery of Eperisone hydrochloride
RU2777644C2 (ru) Системы доставки для местного нанесения для активных веществ

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: LYOTROPIC DELIVERY SYSTEMS LTD

Free format text: FORMER NAME(S): YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD; LYOTROPIC DELIVERY SYSTEMS (LDS)

Owner name: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD

Free format text: FORMER NAME(S): YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD; LYOTROPIC DELIVERY SYSTEMS (LDS)

FGA Letters patent sealed or granted (standard patent)